T-cell receptor (TCR) recognizing S-488410 peptide–HLA-A*24:02 complexes (S-488410-specific TCR)

The T-cell receptor (TCR) on cytotoxic T lymphocytes (CTLs) recognizing S-488410 peptide–HLA-A*24:02 complexes is a critical component of the adaptive immune response targeted by cancer immunotherapy. S-488410 is a multi-peptide vaccine consisting of five synthetic peptides derived from oncoantigens frequently overexpressed in various cancers, including DEPDC1, MPHOSPH1, CDCA1, KIF20A, and ECT2. When these peptides are presented by the HLA-A*24:02 molecule, they are recognized by specific TCRs, leading to the activation and expansion of CTLs capable of identifying and lysing tumor cells. This target is primarily relevant in the treatment of esophageal cancer and head and neck squamous cell carcinoma in patients who are HLA-A*24:02 positive. By engaging these specific TCRs, the therapy aims to overcome tumor-induced immunosuppression and establish a robust, antigen-specific anti-tumor response.

Other names

S-488410-specific T-cell receptorDEPDC1/MPHOSPH1/CDCA1/KIF20A/ECT2-specific TCRFive-peptide cancer vaccine-specific TCR

S-488410 is a cocktail of five HLA-A*24:02-restricted synthetic peptides derived from oncoantigens (DEPDC1, MPHOSPH1, CDCA1, KIF20A, and ECT2). These peptides bind to HLA-A*24:02 on the surface of antigen-presenting cells, which then present them to the T-cell receptor (TCR) on cytotoxic T lymphocytes (CTLs). This interaction triggers the activation and proliferation of antigen-specific CTLs that recognize and kill tumor cells expressing these specific oncoantigens.